Quantitative Pharmacodynamic Analysis of Trimethoprim‐Sulfonamide Combination Activity Against Staphylococcus pseudintermedius
Abstract
Trimethoprim (TMP)‐sulfonamide combinations are widely used in veterinary medicine, yet the quantitative nature of their pharmacodynamic interaction remains incompletely characterised. This study investigated the interaction between TMP and sulfamethoxazole (SMX), sulfadiazine (SDZ) and sulfadimethoxine (SDMX) against two Staphylococcus pseudintermedius isolates using minimum inhibitory concentration (MIC) testing, time‐kill curve (TKC) experiments and semi‐mechanistic pharmacodynamic modelling incorporating a General Pharmacodynamic Interaction (GPDI) framework. TKC assays demonstrated enhanced antibacterial activity for TMP‐sulfonamide combinations compared with monotherapy, with the greatest bacterial killing observed at TMP:sulfonamide ratios of 1:4 and 1:19. The final GPDI model identified a predominantly unidirectional interaction in which sulfonamides increased TMP potency through concentration‐dependent reductions in TMP EC 50 of 86%–96% at saturating sulfonamide concentrations, corresponding to approximately 7‐ to 26‐fold maximal possible increases in TMP potency. Maximal synergy differed between sulfonamides, occurring at approximately 1:20 for TMP/SMX (~75% increase in killing), 1:40 for TMP/SDZ (~181%) and 1:5 for TMP/SDMX (~80%). Pharmacokinetic‐pharmacodynamic simulations of clinically relevant canine dosing regimens predicted transient bacterial suppression but not bacterial eradication. These findings demonstrate that TMP‐sulfonamide synergy is dynamic, concentration‐dependent and bacterial species‐specific, highlighting the importance of PK/PD‐informed optimisation of potentiated sulfonamide therapy in veterinary medicine.
Related
- Unraveling Trimethoprim-Sulfonamide synergy against Escherichia coli through semi-mechanistic PK/PD modeling
- Clinical pharmacokinetic-pharmacodynamic relationships between drug exposure and the QT/QTc interval: Protocol for a systematic review and quantitative synthesis
- Trimethoprim suppress phage activity and reduces toxin production in a clinical STEC strain, even in the presence of DNA-damaging antibiotics
- Population pharmacokinetic modeling of sulfamethoxazole, sulfadiazine and sulfadimethoxine combined with trimethoprim in calves
- Prior-informed population pharmacokinetic-pharmacodynamic modeling of dexamethasone in horses
BibTeX
@article{mead2026quantitative,
title = {{Quantitative Pharmacodynamic Analysis of Trimethoprim‐Sulfonamide Combination Activity Against Staphylococcus pseudintermedius}},
author = {Andrew Mead and Alexis Viel and Marine Boulanger and Gudrun Overesch and Carl Ekstrand and Pierre‐louis Toutain and Aude Ferran and Ludovic Pelligand},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2026},
month = sep,
doi = {10.1111/jvp.70107},
url = {https://hal.science/hal-05746412v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Quantitative Pharmacodynamic Analysis of Trimethoprim‐Sulfonamide Combination Activity Against Staphylococcus pseudintermedius
AU - Andrew Mead
AU - Alexis Viel
AU - Marine Boulanger
AU - Gudrun Overesch
AU - Carl Ekstrand
AU - Pierre‐louis Toutain
AU - Aude Ferran
AU - Ludovic Pelligand
PY - 2026
DA - 2026/09/09
JO - Journal of Veterinary Pharmacology and Therapeutics
DO - 10.1111/jvp.70107
UR - https://hal.science/hal-05746412v1
AB - Trimethoprim (TMP)‐sulfonamide combinations are widely used in veterinary medicine, yet the quantitative nature of their pharmacodynamic interaction remains incompletely characterised. This study investigated the interaction between TMP and sulfamethoxazole (SMX), sulfadiazine (SDZ) and sulfadimethoxine (SDMX) against two Staphylococcus pseudintermedius isolates using minimum inhibitory concentration (MIC) testing, time‐kill curve (TKC) experiments and semi‐mechanistic pharmacodynamic modelling incorporating a General Pharmacodynamic Interaction (GPDI) framework. TKC assays demonstrated enhanced antibacterial activity for TMP‐sulfonamide combinations compared with monotherapy, with the greatest bacterial killing observed at TMP:sulfonamide ratios of 1:4 and 1:19. The final GPDI model identified a predominantly unidirectional interaction in which sulfonamides increased TMP potency through concentration‐dependent reductions in TMP EC 50 of 86%–96% at saturating sulfonamide concentrations, corresponding to approximately 7‐ to 26‐fold maximal possible increases in TMP potency. Maximal synergy differed between sulfonamides, occurring at approximately 1:20 for TMP/SMX (~75% increase in killing), 1:40 for TMP/SDZ (~181%) and 1:5 for TMP/SDMX (~80%). Pharmacokinetic‐pharmacodynamic simulations of clinically relevant canine dosing regimens predicted transient bacterial suppression but not bacterial eradication. These findings demonstrate that TMP‐sulfonamide synergy is dynamic, concentration‐dependent and bacterial species‐specific, highlighting the importance of PK/PD‐informed optimisation of potentiated sulfonamide therapy in veterinary medicine.
SN - 0140-7783
SN - 1365-2885
ER -